Filtering by:
Targeted Therapy2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
New Drug Reduces Recurrence Risk for Some Women With Early-Stage Breast Cancer
Research presented at the San Antonio Breast Cancer Symposium may result in a new standard of care for some people with HER2 positive, early stage breast cancer.
FDA Approves 2 Drugs for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved 2 new drugs, Daurismo (glasdegib) and Venclexta (venetoclax), to treat people newly diagnosed with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
FDA Approves Tibsovo (Ivosidenib) for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved the targeted therapy drug Tibsovo (ivosidenib) to treat some adults with a certain type of acute myeloid leukemia (AML).
FDA Approves Drug Combination for Aggressive Type of Thyroid Cancer
The US Food and Drug Administration (FDA) has approved a combination of 2 targeted drugs to treat people with anaplastic thyroid cancer that has a certain type of gene mutation (BRAF V600E) and cannot be completely removed through surgery.
FDA Approves First Drug Specifically for BRCA-mutated Breast Cancer
The US Food and Drug Administration (FDA) has for the first time approved a treatment specifically for a type of breast cancer caused by a mutated BRCA gene: Lynparza (olaparib).
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Expands Approval for Sutent (Sunitinib) After Kidney Cancer Surgery
The US Food and Drug Administration (FDA) has approved Sutent (sunitinib) to treat adults who are at high risk of kidney cancer returning after they’ve had a nephrectomy, surgical removal of a kidney.